These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 71400)

  • 1. Polymorphic hydroxylation of Debrisoquine in man.
    Mahgoub A; Idle JR; Dring LG; Lancaster R; Smith RL
    Lancet; 1977 Sep; 2(8038):584-6. PubMed ID: 71400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
    Du YL; Lou YQ
    Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The polymorphic 4-hydroxylation of debrisoquine in a Saudi arab population.
    Islam SI; Idle JR; Smith RL
    Xenobiotica; 1980 Nov; 10(11):819-25. PubMed ID: 7467397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphic 4-hydroxylation of debrisoquine in chronic discoid psoriasis.
    Chapman PH; Rawlins MD; Shuster S; Idle JR; Ritchie JC; Smith RL
    Eur J Clin Pharmacol; 1981; 21(3):257-8. PubMed ID: 6895622
    [No Abstract]   [Full Text] [Related]  

  • 5. A study of the debrisoquine hydroxylation polymorphism in a Nigerian population.
    Mbanefo C; Bababunmi EA; Mahgoub A; Sloan TP; Idle JR; Smith RL
    Xenobiotica; 1980 Nov; 10(11):811-8. PubMed ID: 7467396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
    Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
    Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of urine pH on debrisoquine phenotyping: application of an HPLC-method.
    Kallio J
    Int J Clin Pharmacol Ther Toxicol; 1990 May; 28(5):223-6. PubMed ID: 2163994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
    Alván G; Grind M; Graffner C; Sjöqvist F
    Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereoselectivity of the 4-hydroxylation of debrisoquine in man, detected by gas chromatography/mass spectrometry.
    Meese CO; Fischer C; Eichelbaum M
    Biomed Environ Mass Spectrom; 1988 Jan; 15(2):63-6. PubMed ID: 3349209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diurnal effects on debrisoquine hydroxylation phenotyping.
    Lee EJ
    Eur J Clin Pharmacol; 1988; 35(4):441-2. PubMed ID: 3197754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population].
    Dick B; Küpfer A; Molnàr J; Braunschweig S; Preisig R
    Schweiz Med Wochenschr; 1982 Jul; 112(30):1061-7. PubMed ID: 7123181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Debrisoquine hydroxylation phenotype in SLE patients.
    Seideman P; Alván G
    Scand J Rheumatol; 1989; 18(1):63-4. PubMed ID: 2704985
    [No Abstract]   [Full Text] [Related]  

  • 13. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J; Lindberg R; Huupponen R; Iisalo E
    Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hydroxylation of debrisoquin in Parkinson's disease].
    Meillard MN; Bentué-Ferrer D; Brunet-Bourgin F; Morel G; Allain H
    Presse Med; 1990 May; 19(20):947-9. PubMed ID: 2141131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liquid chromatographic assay for debrisoquine and 4-hydroxydebrisoquine in urine.
    Westwood BE; Harman PJ; Mashford ML
    J Chromatogr; 1986 Jan; 374(1):200-3. PubMed ID: 3949930
    [No Abstract]   [Full Text] [Related]  

  • 16. Metabolism of debrisoquine sulfate. Identification of some urinary metabolites in rat and man.
    Allen JG; East PB; Francis RJ; Haigh JL
    Drug Metab Dispos; 1975; 3(5):332-7. PubMed ID: 241613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
    Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A
    Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1988 May; 7(3):273-6. PubMed ID: 3391625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid liquid chromatographic determination of debrisoquine and its hydroxy metabolite in human urine to define hydroxylation phenotypes.
    Duche JC; Barre J; Tillement JP
    J Chromatogr; 1987 Dec; 423():340-3. PubMed ID: 3443670
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.
    Dalén P; Dahl M; Andersson K; Bertilsson L
    Br J Clin Pharmacol; 2000 Feb; 49(2):180-4. PubMed ID: 10671914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.